A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 3,625,467 shares of PRQR stock, worth $12.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,625,467
Previous 3,625,467 -0.0%
Holding current value
$12.3 Million
Previous $8.3 Million 27.51%
% of portfolio
0.01%
Previous 0.02%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$0.8 - $3.7 $260,373 - $1.2 Million
325,467 Added 9.86%
3,625,467 $13.4 Million
Q1 2022

May 16, 2022

SELL
$0.9 - $8.39 $1.27 Million - $11.9 Million
-1,415,152 Reduced 30.01%
3,300,000 $2.99 Million
Q3 2021

Nov 15, 2021

BUY
$5.16 - $8.47 $106,744 - $175,218
20,687 Added 0.44%
4,715,152 $39.5 Million
Q1 2021

May 17, 2021

BUY
$4.14 - $9.22 $597,828 - $1.33 Million
144,403 Added 3.17%
4,694,465 $31 Million
Q1 2020

May 15, 2020

SELL
$5.25 - $9.9 $111,599 - $210,444
-21,257 Reduced 0.47%
4,550,062 $25 Million
Q4 2019

Feb 14, 2020

BUY
$5.84 - $10.51 $4.88 Million - $8.78 Million
835,812 Added 22.37%
4,571,319 $45.3 Million
Q4 2018

Feb 14, 2019

BUY
$15.25 - $22.4 $4.17 Million - $6.13 Million
273,566 Added 7.9%
3,735,507 $58.9 Million
Q3 2018

Nov 14, 2018

BUY
$6.45 - $21.6 $8.38 Million - $28.1 Million
1,299,414 Added 60.09%
3,461,941 $67 Million
Q2 2018

Aug 14, 2018

BUY
$2.95 - $7.45 $1.95 Million - $4.94 Million
662,527 Added 44.17%
2,162,527 $15.8 Million
Q1 2018

May 15, 2018

BUY
$2.9 - $3.5 $1.45 Million - $1.75 Million
500,000 Added 50.0%
1,500,000 $4.61 Million
Q4 2017

Feb 14, 2018

BUY
$2.8 - $4.8 $2.8 Million - $4.8 Million
1,000,000
1,000,000 $3.23 Million

Others Institutions Holding PRQR

About ProQR Therapeutics N.V.


  • Ticker PRQR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,362,096
  • Market Cap $241M
  • Description
  • ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...
More about PRQR
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.